Mark L Baum bought $302K of Harrow (HROW)
Executed May 14, disclosed May 15, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 15), the stock returned +21.9% (delay-adjusted); from the execution session (May 14), +28.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Mark L Baum (CHIEF EXECUTIVE OFFICER) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Harrow, Inc. (HROW). Across 1 priced purchase filing, the average 21-session return was +28.2% from execution and +21.9% from disclosure (delay-adjusted; derived). The largest single filing was $302K of HROW (10,000 sh × $30.20, as filed), executed May 14.
Healthcare · Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→